September 23, 2024
September 23, 2024- Our research article is published on Nature Nanotechnology, reporting the generation of a graphene oxide antigen-presenting platform... Read More
Our research centers on deciphering the cellular and molecular mechanisms controlling antitumor immunity, and exploiting knowledge to device the next-generation cancer immunotherapies.
Two active research directions are:
1.Identify new immune checkpoints and develop new immune checkpoint blockade therapy for cancer.
2. Develop novel “off-the-shelf” allogeneic immune cell therapies for cancer.
Zhu E*, Yu J*, Li, Y-R, Ma F, Wang Y-C, Liu Y, Li M, Kim YJ, Zhu Y, Hahn Z, Zhou Y, Brown J, Zhang Y, Pellegrini M, Hsiai T, Yang L* and Huang Y#. (*Co-first authors; #Co-corresponding authors). Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies. Nat. Nanotechnol. 2024, September 23. doi: 10.1038/s41565-024-01781-4. Online ahead of print. [Nature Nanotechnology PDF][UCLA Health News PDF][UCLA BSCRC News PDF][UCLA CNSI News PDF][AAAS EurekAlert! PDF]
Li Y-R*, Zhou Y*, Yu J*, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang Y-C, Li Z, Yu Y, Dunn ZS, Guo W, Cen X, Husman T, Bajpai A, Kramer A, Wilson M, Fang Y, Huang J, Li S, Zhou Y, Zhang Y, Hahn Z, Zhu E, Ma F, Pan C, Lusis AJ, Zhou JJ, Seet CS, Kohn DB, Wang P, Zhou XJ, Pellegrini M, Puliafito BR, Larson SM, and Yang L. (*Co-first authors) Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 2024, May 14. doi: 10.1038/s41587-024-02226-y. Online ahead of print. [Nature Biotechnology PDF][Nature Biotechnology News & Views PDF][Nature Portfolio PDF][UCLA Newsroom PDF][UCLA Health News PDF][UCLA BSCRC News PDF][Bioquick News PDF]
Lee D*, Dunn ZS*, Guo W*, Rosenthal CJ, Penn NE, Yu Y, Zhou K, Li Z, Ma F, Li M, Song T-C, Cen X, Li Y-R, Zhou JJ, Pellegrini M, Wang P, and Yang L. (*Co-first authors) Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering. Nat Commun. 2023, 14(1):6942. doi: 10.1038/s41467-023-42619-2. [Nature Communications PDF][UCLA News PDF][Springer Nature Blog PDF]
September 23, 2024- Our research article is published on Nature Nanotechnology, reporting the generation of a graphene oxide antigen-presenting platform... Read More
June 14, 2024- Our Postdoctoral Scholar, Charlie Yan-Ruide Li, wins the 2024 UCLA Microbiology, Immunology & Molecular Genetics (MIMG) Department... Read More
May 30, 2024- Dr. Lili Yang receives a $6.3 million CIRM Partnering Opportunity for Translational Research Projects Award to translate... Read More
We are currently recruiting PhD students (2 openings) and postdoctoral researchers (1 opening). Welcome to apply! [PhD Openings][Postdoc Openings]... Read More
May 11, 2021- Our off-the-shelf cell therapy technology is licensed by a Biotech startup, Appia Bio, for commercial development. The... Read More